Here, we demonstrated that targeting the ATR/CHK1 axis triggers cancer cell-intrinsic immunogenicity by the STING-mediated DNA-sensing pathway to enhance the therapeutic efficacy of radiotherapy and ICBs in ARID1A-deficient tumors. The gene discussed is CHEK1; the disease is cancer.